Article
Washington, D.C. - In a recent 10-week, three-dose phase II trial of inflaximab (Remicade), 87.9 percent of the 250 participants achieved PASI 75, while 58 percent achieved PASI 90 at the 10-week mark.
Nutraceuticals: A Boost for Skin Health
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
What’s Next for Topical JAK Inhibitors?
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Day 1 Recap: SBS 2025
Tips and Tricks for Successful Practice Management with Leon Kircik, MD